The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Open accessPublished version of a preprint
Abstract
Purpose: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as these may influence individual treatment selection or sequence. We aimed to identify baseline factors associated with overall survival (OS) after pembrolizumab treatment in melanoma patients. Experimental Design: Serum lactate dehydrogenase (LDH), routine blood count parameters, and clinical characteristics were investigated in 616 patients. Endpoints were OS and best overall response following pembrolizumab treatment. Kaplan–Meier analysis and Cox regression were applied for survival analysis. Results: Relative eosinophil count (REC) ≥1.5%, relative lymphocyte count (RLC) ≥17.5%, ≤2.5-fold elevation of LDH, and the absence of metastasis other than soft-tissue/lung were associated with favorable OS in the discovery (n = 177) and the confirmation (n = 182) cohort and had independent positive impact (all P < 0.001). Their independent role was subsequently confirmed in the validation cohort (n = 257; all P < 0.01). The number of favorable factors was strongly associated with prognosis. One-year OS probabilities of 83.9% versus 14.7% and response rates of 58.3% versus 3.3% were observed in patients with four of four compared to those with none of four favorable baseline factors present, respectively. Conclusions: High REC and RLC, low LDH, and absence of metastasis other than soft-tissue/lung are independent baseline characteristics associated with favorable OS of patients with melanoma treated with pembrolizumab. Presence of four favorable factors in combination identifies a subgroup with excellent prognosis. In contrast, patients with no favorable factors present have a poor prognosis, despite pembrolizumab, and additional treatment advances are still needed. A potential predictive impact needs to be further investigated. Clin Cancer Res; 22(22); 5487–96. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, an elevated eosinophil count prior to treatment was associated with longer overall survival in several studies.8–12”
In the citing paper
“Other pre-treatment immunological factors associated with improved treatment responses include high eosinophil and lymphocyte blood counts, an abundance of CD8+ T cells infiltrating the tumor or present at the tumor margin, and increased serum TGF-β levels in melanoma patients treated with anti-PD-1 (88, 91, 92, 109).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [109]
In the citing paper
“Importantly, it has been shown that investigating several biomarkers in combination can improve treatment predictions (109).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [109]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Blocking antibodies targeting PD-1 or its counterpart PD-L1 can prevent this form of T cell inactivation (1, 10, 18, 34) ensuring sustained antitumor activity.”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Cited by
Sorted by citations
Items 501–585 of 585
Wu, Y., Zhu, X., & Zhu, L. (2022) · Current Protein and Peptide Science · doi:10.2174/1389203723666220620161742 · Cited by 1
NGS Analysis of Plasma cfDNA and cfmiRNA Signatures in Melanoma Brain Metastasis Patients
Ramos, R. I., Lin, S. Y., Bustos, M. A., Eisenberg, A., Ryu, S., Tran, L. T., Kelly, D. F., & Hoon, D. S. �. (2023) · Current cancer research · doi:10.1007/978-3-031-22903-9_19 · Cited by 1
Zhang, M., Hao, J., Wu, Y., Gao, Z., & Wang, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1411548 · Cited by 1
Nunes, L. F., de Oliveira, L. C., Barcauí, C. B., Mendes, G. L. Q., Thuler, L. C., & Bergmann, A. K. (2025) · Indian Journal of Dermatology Venereology and Leprology · doi:10.25259/ijdvl_1198_2024 · Cited by 1
KEYNOTE-006: a success in melanoma, but a long way to go
Wistuba‐Hamprecht, K., & Pawelec, G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31816-0 · Cited by 1
Diagnosis of Stage IV Melanoma
Tarhini, A. A., Agarwala, S. S., Khunger, A., Wahl, R. L., & Balch, C. M. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_29-1 · Cited by 1
3D culture systems as models for solid tumors and cancer metabolism
Celeiro, S. P., Baltazar, F., & Viana‐Pereira, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818128-7.00006-x · Cited by 1
Vaincre les résistances aux antagonistes de checkpoint en augmentant l’immunogénicité de la tumeur
Marabelle, A. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.02.002 · Cited by 1
Predictive Biomarkers of Melanoma
Hanly, A. M., Gibson, F. T., & Alani, R. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-82639-0_16 · Cited by 1
Biomarkers for Cancer Immunotherapy
Ahsan, H., Islam, S. U., Ahmed, M. B., Lee, Y. S., Qayum, M., & Sonn, J. K. (2022) · Springer eBooks · doi:10.1007/978-981-16-5759-7_9 · Cited by 1
Beitraege zur Systematik der Tribus Mesochorini Japans (Hym. Ichneumonidae)
Uchida, T. (1933) · Hokkaido University Collection of Scholarly and Academic Papers (Hokkaido University) · Cited by 1
PD-1 negatively regulates helper T cell differentiation into Th2Preprint
Tajima, M., Ikuta, N., Nakajima, Y., Suzuki, K., Tokumaru, Y., Li, P., Kiyonari, H., Honjo, T., & Ohta, A. (2024) · eLife · doi:10.7554/elife.100879.1 · Cited by 1
Biomarkers for outcome upon MAPK inhibition in melanoma
Blank, C. U. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30593-9
Self-citationAktuelle Immuntherapien des malignen Melanoms
Pietschke, K., Lomberg, D., & Eigentler, T. (2017) · Info Onkologie · doi:10.1007/s15004-017-5788-3
Aktuelle Immuntherapien des malignen Melanoms
Pietschke, K., Lomberg, D., & Eigentler, T. (2018) · hautnah dermatologie · doi:10.1007/s15012-018-2634-8
Immune Checkpoint Inhibitor Therapy: A Boon to Elderly Patients with Advanced Melanoma?
Muta, T. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0686-17
Perez, M. C., Yu, H.-H. M., & Markowitz, J. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-226089
Overview of Microsatellite Instability and Immune Checkpoint Inhibitors in Colorectal Cancer
Kim, D. W., Lee, J.-H., Kim, K., & Imanirad, I. (2018) · Current Colorectal Cancer Reports · doi:10.1007/s11888-018-0413-x
Immunologische Grundlagen moderner (Tumor‑)Immuntherapie
Bopp, T., & Schild, H. (2018) · Der Pathologe · doi:10.1007/s00292-018-0517-8
Immunologische Grundlagen moderner (Tumor‑)Immuntherapie
Bopp, T., & Schild, H. (2019) · best practice onkologie · doi:10.1007/s11654-018-0112-8
Usefulness of serum 5－S－cysteinyldopa as a biomarker in targeted therapy for metastatic melanoma
Omodaka, T., Minagawa, A., Koga, H., Wakamatsu, K., & Okuyama, R. (2019) · Skin Cancer · doi:10.5227/skincancer.34.10
In the literature: February 2020
Roda, D., Gambardella, V., Cejalvo, J. M., & Cervantes, A. M. R. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000680
The Laboratory Evaluation of Melanoma
Lullo, J. J., & Shitabata, P. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-27400-9_3
An overview on precision therapy in bladder cancer
Sayed, A., Munir, M., Eweis, N., Wael, D., Shazly, O., Awad, A. K., Elbadawy, M. A., & Eissa, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1801346
Marconcini, R. (2021) · Open Access Journal of Oncology and Medicine · doi:10.32474/oajom.2021.04.000187
Glucose metabolism in cancer: heterogeneity and potentials for targeting in patients
Hendriks, A. M. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.178801097
Practical Management of Melanoma
Keung, E. Z.-Y., & Naylor, M. F. (2021) · Springer eBooks · doi:10.1007/978-3-030-50593-6_15
Schadendorf, D., Flaherty, K. T., Duncan, L. M., Kashani–Sabet, M., & Ugurel, S. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_45-1
Self-citationKoubaissi, S. A., Wehbe, H., Kozah, M., Tfayli, A., & Faress, J. A. (2020) · doi:10.22541/au.159112168.89359179
Cheng, Y., Ye, S., Chen, P., Hu, J., Lin, Z.-S., Wu, X., & Lan, P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3782439
Aktuelle Immuntherapien des malignen Melanoms
Pietschke, K., Lomberg, D., & Eigentler, T. (2018) · Im Focus Onkologie · doi:10.1007/s15015-018-3604-z
Novello, S., Migliaretti, G., Galetta, D., Tabbò, F., Montrone, M., Alemanni, A., Genestroni, S., Stura, I., Vavalà, T., Buosi, R., et al. (2021) · Advanced Biomedicine · doi:10.54730/abm.2021.030503
ImmunoPET Imaging of Immune Checkpoints to Assess Their Cancer Therapeutic Potential
Wynter, C., Murugesan, N., & Natarajan, A. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_170-1
Melanome der Haut und Schleimhaut
Schilling, B., & Gesierich, A. (2022) · Springer eBooks · doi:10.1007/978-3-662-62808-9_8
Self-citationPredictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma
Bobak, K., Synoradzki, K. J., Sulejczak, D., Rutkowski, P. L., & Czarnecka, A. M. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_179-1
Paidi, S. K., Troncoso, J. R., Raj, P., Díaz, P. M., Ivers, J. D., Lee, D. E., Avaritt, N. L., Gies, A. J., Quick, C. M., Byrum, S. D., et al. (2023) · doi:10.1158/0008-5472.c.6513670.v1
Paidi, S. K., Troncoso, J. R., Raj, P., Díaz, P. M., Ivers, J. D., Lee, D. E., Avaritt, N. L., Gies, A. J., Quick, C. M., Byrum, S. D., et al. (2023) · doi:10.1158/0008-5472.c.6513670
Basler, L., Gabryś, H. S., Hogan, S. A., Pavic, M., Bogowicz, M., Vuong, D., Tanadini‐Lang, S., Forster, R. E., Kudura, K., Huellner, M. W., et al. (2023) · doi:10.1158/1078-0432.22478060.v1
Self-citationBasler, L., Gabryś, H. S., Hogan, S. A., Pavic, M., Bogowicz, M., Vuong, D., Tanadini‐Lang, S., Forster, R. E., Kudura, K., Huellner, M. W., et al. (2023) · doi:10.1158/1078-0432.c.6529838.v1
Self-citationTriozzi, P. L., Stirling, E. R., Song, Q., Westwood, B. M., Kooshki, M., Forbes, M. E., Holbrook, B. C., Cook, K. L., Alexander‐Miller, M. A., Miller, L. D., et al. (2023) · doi:10.1158/1078-0432.c.6532389
Zhu, K., Xiong, L., Xiong, J., Zhu, Y. J., Liang, Y., & Yu, D. (2023) · Research Square · doi:10.21203/rs.3.rs-3115047/v1
Hou, Q., Li, H., Liang, Y., Yao, N., Cao, X., Liu, J., Sun, B., Feng, P., Zhang, W., & Cao, J. (2023) · Cancer Biomarkers · doi:10.3233/cbm-230067
Eosinophilia as a Predictive Biomarker for Melanoma Treatment, A Single Center Review
Reuben, D. Y. (2023) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2023.53.008338
Hypereosinophilia with Renal Injury Caused by Immune Checkpoint Inhibitor
Schiappacasse, G. (2023) · Journal on oncology · doi:10.52768/2692-563x/1109
Tan, J., Huang, X., Dong, Y., & Li, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4144117/v1
马, 凤. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1451485
PD-1 negatively regulates helper T cell differentiation into Th2Preprint
Tajima, M., Ikuta, N., Nakajima, Y., Suzuki, K., Tokumaru, Y., Li, P., Kiyonari, H., Honjo, T., & Ohta, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.26.605269
PD-1 negatively regulates helper T cell differentiation into Th2Preprint
Tajima, M., Ikuta, N., Nakajima, Y., Suzuki, K., Tokumaru, Y., Li, P., Kiyonari, H., Honjo, T., & Ohta, A. (2024) · eLife · doi:10.7554/elife.100879
Emerging Biomarkers of Response to Immunotherapy: Host Characteristics in Breast Cancer
Mathesh, V., & Reddy, S. M. (2025) · Cancer immunotherapy · doi:10.1007/13905_2024_44
Nibeyro, G., Baronetto, V. M., Nava, A., Girotti, M. R., Prato, L. B., Morón, G., & Fernández, E. A. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0204
Devkirti, A. (2024) · Journal of Student Research · doi:10.47611/jsrhs.v13i4.7542
Nicola, C., Pédard, M., Dubois, M., Desrues, L., Neveu, P., Riou, G., Johnston, I., Kleouforo, P. D., Lecras, P., Vaudry, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.03.673981
Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma
Bobak, K., Synoradzki, K. J., Sulejczak, D., Rutkowski, P. L., & Czarnecka, A. M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_179
ImmunoPET Imaging of Immune Checkpoints to Assess Their Cancer Therapeutic Potential
Wynter, C., Murugesan, N., & Natarajan, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_170
Genetic and Epigenetic Indicators Predicting Response to Immune Checkpoint Inhibitors
Yang, J., Wang, B., Sun, Q., & Cai, D. (2025) · Bulletin of pioneering researches of medical and clinical science · doi:10.51847/jv5favsxwc
Hypereosinophilia after CAR T-cell therapy
Poirier, B., Houot, R., Vic, S., Roussel, M., Henry, C., Pastoret, C., & Messéant, O. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2565466
Wu, L., Pan, C., Wang, W., Gao, Y., Cui, X., Xie, S., Yang, B., Yuan, J., Chen, M., Zhang, J., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14874-7
Exploring blood cell biomarkers in melanoma patients receiving adjuvant anti‐ PD ‐1 immunotherapy
Teixeira, R. D. J., Sorroche, B. P., de Souza, V. G., de Araujo, T. E., Paes, V., Tosi, I. C., Ziquiel, L. R., Crespí-Payeras, F., Mateu, J., Ertekin, S. S., et al. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70164
Capone, M., Fratangelo, F., Giannarelli, D., Sorrentino, C., Turiello, R., Zanotta, S., Galati, D., Madonna, G., Tuffanelli, M., Scarpato, L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11972547
Self-citationGrabbe, P., Gschwendtner, K. M., Maatouk, I., Strobel, S. B., Salzmann, M., Bossert, J., Eich, W., Wild, B., Meier, F., Hassel, J. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457227
Self-citationGuo, Y., Pan, Y., Wan, J., Gong, B., Li, Y., Xuefeng, K., & Zheng, C. (2024) · Figshare · doi:10.6084/m9.figshare.25698252
Grabbe, P., Gschwendtner, K. M., Maatouk, I., Strobel, S. B., Salzmann, M., Bossert, J., Eich, W., Wild, B., Meier, F., Hassel, J. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457230
Self-citationCapone, M., Fratangelo, F., Giannarelli, D., Sorrentino, C., Turiello, R., Zanotta, S., Galati, D., Madonna, G., Tuffanelli, M., Scarpato, L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11972556
Self-citationGrabbe, P., Gschwendtner, K. M., Maatouk, I., Strobel, S. B., Salzmann, M., Bossert, J., Eich, W., Wild, B., Meier, F., Hassel, J. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457221
Self-citationGrabbe, P., Gschwendtner, K. M., Maatouk, I., Strobel, S. B., Salzmann, M., Bossert, J., Eich, W., Wild, B., Meier, F., Hassel, J. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457224
Self-citationCapone, M., Fratangelo, F., Giannarelli, D., Sorrentino, C., Turiello, R., Zanotta, S., Galati, D., Madonna, G., Tuffanelli, M., Scarpato, L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11972565
Self-citationGrabbe, P., Gschwendtner, K. M., Maatouk, I., Strobel, S. B., Salzmann, M., Bossert, J., Eich, W., Wild, B., Meier, F., Hassel, J. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457233
Self-citationImmunotherapy of Melanoma – Current State of Knowledge and Future Perspectives
Wiśniewska, D., Jamro, A., Jucha, D., Klimas, M., Winiarska, M., & Krupa-Nurcek, S. (2025) · Medical Science · doi:10.54905/disssi.v29i166.e222ms3721
Chevrier, S., Richard, C., Adotévi, O., Ayyoub, M., Chaput, N., Damotte, D., Ghiringhelli, F., Hacein‐Bey‐Abina, S., Tartour, É., Zitvogel, L., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2306
Sato, S., Kagabu, M., Jo, A., Otsuka, H., Kitamura, A., Musashi, M., Jonai, N., CHIBA, Y., Takatori, E., Kaido, Y., et al. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-02960-0
Tissue Injury and Biomaterial Treatment Modulate Tumor Growth and Response to ImmunotherapyPreprint
Ruta, A., Gray-Gaillard, E. F., Garcia, J. A., Huyer, L. D., Mathkour, Y., Cherry, C., Patatanian, M., Mejías, J. C., Maestas, D. R., Krishnan, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.02.703323
Chen, J.-M., Li, S. L., Liu, R., Yin, Z., Quan, Q., Ling, D.-F., Long, H.-X., Yuan, L., Xu, M., Tang, L.-Q., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1775584
Integrated analysis and clinical impact of immune and stromal microenvironments in solid tumors
Petitprez, F. (2018) · theses.fr (ABES) · doi:10.70675/cea357bazafbaz4eaaz94e5zc5f644de5018
Malissen, N. (2018) · theses.fr (ABES) · doi:10.70675/6e683c4ez28c0z442azaf6az7efb18488bc9
Jiang, W., Mo, T., Chen, C., Feng, J., & Wang, W. (2026) · iScience · doi:10.1016/j.isci.2026.115765
Shi, Y., Savchenko, A., Brase, J. C., Reardon, B. M., Ricker, C. A., Park, J., Tarantino, G., Manos, M. P., Huang, A. Y., Allen, E. M. V., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.09.721157
Noninvasive in vivo imaging of NF-κB activation predicts immunotherapy response in solid tumors
Stowbur, D., Mehling, R., Knopf, P., Schörg, B. F., Sonanini, D., Arnold-Schild, D., González-Menéndez, I., Quintanilla-Martinez, L., Fehrenbacher, B., Schaller, M., et al. (2026) · npj Imaging · doi:10.1038/s44303-026-00173-8
Real-world predictors of survival and response in advanced melanomaPreprint
Hathi, D., Chi, L., Wu, N., Nkhoma, E., Harnett, J., Salvati, M. E., Lewis, K., & Li, Y. (2026) · Research Square · doi:10.21203/rs.3.rs-9656125/v1
Pan, Y., Li, Q., Tang, H., Chen, G., & Li, D. (2026) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s623481
Toshev, S., Jalalova, D., Tastanova, G., Nurmatova, I., Latipov, I., & Ismoilov, O. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04584-2
Metadata
- Authors
- Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., Brenner, N., Kähler, K., Heinzerling, L., Gutzmer, R., Bender, A., Gebhardt, C., Romano, E., Meier, F., Martus, P., Maio, M., Blank, C., Schadendorf, D., Dummer, R., Ascierto, P. A., Hospers, G., Garbe, C., & Wolchok, J. D.
- Affiliations
- Universitätsklinikum Tübingen (DE)
- Heidelberg University (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Memorial Sloan Kettering Cancer Center (US)
- University Medical Center Groningen (NL)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- 10Department of Dermatology, University of Zürich, Zürich, Switzerland.
- 12Division of Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy.
- University Hospital Cologne (DE)
- University Hospital Schleswig-Holstein (DE)
- Universitätsklinikum Erlangen (DE)
- Medizinische Hochschule Hannover (DE)
- Universitätsklinikum Gießen und Marburg (DE)
- German Cancer Research Center (DE)
- Institut Curie (FR)
- University of Tübingen (DE)
- University of Siena (IT)
- The Netherlands Cancer Institute (NL)
- University of Zurich (CH)
- Corresponding author
- Weide, Benjamin
- ORCID
- Weide, Benjamin
- Hassel, Jessica C.
- Berking, Carola
- Postow, Michael A.
- Bisschop, Kees
- Simeone, Ester
- Schilling, Bastian
- Brenner, Nicole
- Kähler, Katharina
- Heinzerling, Lucie
- Gutzmer, Ralf
- Gebhardt, Christoffer
- Romano, Emanuela
- Meier, Friedegund
- Martus, Peter
- Maio, Michele
- Blank, Christian
- Schadendorf, Dirk
- Dummer, Reinhard
- Ascierto, Paolo A.
- Hospers, Geke
- Garbe, Claus
- Wolchok, Jedd D.
- Venue
- Clinical Cancer Research
- Published
- 2016-11-14
- Volume
- 22
- Issue
- 22
- Pages
- 5487-5496
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC5572569
- OpenAlex
- W2397854274
- Semantic Scholar
- b5a9c4e2d6333e54d55ec140895bb53cebb851f9
- Cited by
- 589
- References
- 44
- Citations by year
- 2026: 17 · 2025: 38 · 2024: 31 · 2023: 46 · 2022: 57 · 2021: 91 · 2020: 86 · 2019: 77 · 2018: 72 · 2017: 59 · 2016: 14
- FWCI
- 39.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma, pembrolizumab, immune checkpoint blockade, prognostic factors, overall survival, lactate dehydrogenase, eosinophil count, lymphocyte count, metastasis, best overall response, predictive biomarkers
- MeSH terms
- Aged, Antibodies, Monoclonal, Female, Humans, L-Lactate Dehydrogenase, Male, Melanoma, Middle Aged, Prognosis, Skin Neoplasms, Biomarkers, Tumor, Cohort Studies, Survival Analysis, Treatment Outcome, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
